Novartis AG
NVS
$119.30
$0.7450.63%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.59% | -15.65% | -19.59% | 124.64% | 111.49% |
| Total Depreciation and Amortization | 75.70% | 62.14% | 47.56% | -63.39% | -60.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 584.76% | 396.33% | 519.40% | -131.38% | -123.22% |
| Change in Net Operating Assets | 42.03% | 36.33% | 4.73% | -122.17% | -29.02% |
| Cash from Operations | 37.99% | 38.01% | 21.86% | -0.31% | -1.95% |
| Capital Expenditure | -26.86% | -24.49% | -28.87% | -26.46% | -25.43% |
| Sale of Property, Plant, and Equipment | -76.68% | -56.82% | -63.71% | 16.00% | 75.69% |
| Cash Acquisitions | 69.25% | 0.40% | -12.83% | -1.15% | -6,136.61% |
| Divestitures | 343.75% | 740.91% | 3,466.67% | -- | -1,166.67% |
| Other Investing Activities | -1,402.34% | -11.48% | -123.27% | -115.37% | -100.90% |
| Cash from Investing | 34.14% | -6.08% | -234.26% | -205.96% | -160.74% |
| Total Debt Issued | 5.07% | 310.19% | 411.84% | 4,403.55% | 2,540.61% |
| Total Debt Repaid | 39.18% | -30.14% | -1.09% | 6.54% | -65.69% |
| Issuance of Common Stock | 4.00% | -- | -81.13% | -81.13% | -84.28% |
| Repurchase of Common Stock | -97.39% | -43.40% | 4.50% | 32.73% | 50.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.54% | -48.84% | -5.09% | -5.09% | -5.09% |
| Other Financing Activities | -110.37% | -104.78% | -105.95% | -101.18% | 4,961.11% |
| Cash from Financing | -74.83% | -47.71% | 17.76% | 47.05% | 54.55% |
| Foreign Exchange rate Adjustments | 355.42% | 106.02% | -398.00% | 117.28% | -199.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 200.00% | -- |
| Net Change in Cash | 58.18% | 5.06% | -132.91% | -67.27% | -141.07% |